These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12369970)

  • 1. Recent advances in the design of iron chelators against oxidative damage.
    Galey JB
    Mini Rev Med Chem; 2001 Sep; 1(3):233-42. PubMed ID: 12369970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
    Bendova P; Mackova E; Haskova P; Vavrova A; Jirkovsky E; Sterba M; Popelova O; Kalinowski DS; Kovarikova P; Vavrova K; Richardson DR; Simunek T
    Chem Res Toxicol; 2010 Jun; 23(6):1105-14. PubMed ID: 20521781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelators can protect against oxidative stress through ferryl heme reduction.
    Reeder BJ; Hider RC; Wilson MT
    Free Radic Biol Med; 2008 Feb; 44(3):264-73. PubMed ID: 18215735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of lipophilic iron chelators as protective agents from oxidative stress.
    Yavin E; Kikkiri R; Gil S; Arad-Yellin R; Yavin E; Shanzer A
    Org Biomol Chem; 2005 Aug; 3(15):2685-7. PubMed ID: 16032345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of U937 cells against oxidative injury by a novel series of iron chelators.
    Galey JB; Destrée O; Dumats J; Pichaud P; Marché J; Génard S; Bracciolli G; Le Capitaine L; Plessix H; Brambilla L; Cantoni O
    Free Radic Biol Med; 1998 Nov; 25(8):881-90. PubMed ID: 9840732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against oxidative damage by iron chelators: effect of lipophilic analogues and prodrugs of N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N'-diacetic acid (OR10141).
    Galey JB; Destrée O; Dumats J; Génard S; Tachon P
    J Med Chem; 2000 Apr; 43(7):1418-21. PubMed ID: 10753479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
    Gaeta A; Molina-Holgado F; Kong XL; Salvage S; Fakih S; Francis PT; Williams RJ; Hider RC
    Bioorg Med Chem; 2011 Feb; 19(3):1285-97. PubMed ID: 21236688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
    Kaiserová H; den Hartog GJ; Simůnek T; Schröterová L; Kvasnicková E; Bast A
    Br J Pharmacol; 2006 Dec; 149(7):920-30. PubMed ID: 17031387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic and natural iron chelators: therapeutic potential and clinical use.
    Hatcher HC; Singh RN; Torti FM; Torti SV
    Future Med Chem; 2009 Dec; 1(9):1643-70. PubMed ID: 21425984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron and iron chelators: a review on potential effects on skin aging.
    Pouillot A; Polla A; Polla BS
    Curr Aging Sci; 2013 Dec; 6(3):225-31. PubMed ID: 23866012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities.
    Hrušková K; Potůčková E; Opálka L; Hergeselová T; Hašková P; Kovaříková P; Šimůnek T; Vávrová K
    Chem Res Toxicol; 2018 Jun; 31(6):435-446. PubMed ID: 29766723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury.
    Hašková P; Jansová H; Bureš J; Macháček M; Jirkovská A; Franz KJ; Kovaříková P; Šimůnek T
    Toxicology; 2016 Sep; 371():17-28. PubMed ID: 27744045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative treatment paradigm for thalassemia using iron chelators.
    Szuber N; Buss JL; Soe-Lin S; Felfly H; Trudel M; Ponka P
    Exp Hematol; 2008 Jul; 36(7):773-85. PubMed ID: 18456387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N,N'-bis-(3,4,5-trimethoxybenzyl) ethylenediamine N,N'-diacetic acid as a new iron chelator with potential medicinal applications against oxidative stress.
    Galey JB; Dumats J; Genard S; Destree O; Pichaud P; Cctroux P; Marrot L; Beck I; Fernandez B; Barre G
    Biochem Pharmacol; 1996 Jan; 51(2):103-15. PubMed ID: 8615878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential use of iron chelators against oxidative damage.
    Galey JB
    Adv Pharmacol; 1997; 38():167-203. PubMed ID: 8895809
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of iron chelation in cancer therapy.
    Buss JL; Torti FM; Torti SV
    Curr Med Chem; 2003 Jun; 10(12):1021-34. PubMed ID: 12678674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
    Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
    Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in iron chelation: an update.
    Heli H; Mirtorabi S; Karimian K
    Expert Opin Ther Pat; 2011 Jun; 21(6):819-56. PubMed ID: 21449664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.